G
Guest
Guest
I found this on the http://www.clinicaltrials.gov,, it`s for Alopecia Areata.. But maye it`s effective for Gentic Alopecia also.. Some Junior`s
have any comments on this?
Targretin® Gel Therapy Helps Treat Patients With Cutaneous T-Cell Lymphoma
Ligand Pharmaceuticals (San Diego, CA) has announced that Targretin® (bexarotene) gel 1% has received approval from the U.S. Food and Drug Administration (FDA) for the topical treatment of cutaneous lesions in patients with early-stage cutaneous T-cell lymphoma (TNM stage IA and IB) who have refractory or persistent disease after other therapies or who have not tolerated other therapies.
Targretin is the first in a novel subclass of retinoid drugs that selectively activates retinoid X receptors. These retinoid receptors have biologic activity distinct from that of retinoic acid receptors. Retinoids are believed to modify the rate of cell growth and the degree of cell differentiation and modulate the expression of apoptosis (controlled cell death). Targretin gel is applied to lesions once every other day for the first week and then increased at weekly intervals to up to four times a day, according to individual lesion tolerance. Sufficient gel should be applied to cover the lesion with a generous coating. The gel should be allowed to dry before covering the lesion with clothing. Occlusive dressings should not be used with Targretin gel. Because unaffected skin may become irritated, avoid applying the gel to normal skin surrounding the lesions. In addition, the gel should not be applied to mucosal surfaces of the body. A response may be seen as soon as four weeks after initiation of therapy, but most patients require longer application. With continued application, further benefit may be obtained. The most common adverse events include rash, pruritis, skin disorder, and pain at the site of application. Targretin gel 1% is supplied in tubes containing 60 g (600 mg active bexarotene).
Targretin gel is the third drug marketed by Ligand Pharmaceuticals for the treatment of cutaneous T-cell lymphoma. Ligand Pharmaceuticals also manufactures Ontak® (denileukin diftitox), an IV treatment indicated for late-stage disease, and Targretin® (bexarotene) capsules, an oral treatment indicated for all stages of disease. Targretin gel is the only topical therapy approved by the FDA for treating patients with cutaneous T-cell lymphoma. For more information, contact Ligand Pharmaceuticals at 800-964-5836 or visit its Web site at http://www.ligand.com/
have any comments on this?
Targretin® Gel Therapy Helps Treat Patients With Cutaneous T-Cell Lymphoma
Ligand Pharmaceuticals (San Diego, CA) has announced that Targretin® (bexarotene) gel 1% has received approval from the U.S. Food and Drug Administration (FDA) for the topical treatment of cutaneous lesions in patients with early-stage cutaneous T-cell lymphoma (TNM stage IA and IB) who have refractory or persistent disease after other therapies or who have not tolerated other therapies.
Targretin is the first in a novel subclass of retinoid drugs that selectively activates retinoid X receptors. These retinoid receptors have biologic activity distinct from that of retinoic acid receptors. Retinoids are believed to modify the rate of cell growth and the degree of cell differentiation and modulate the expression of apoptosis (controlled cell death). Targretin gel is applied to lesions once every other day for the first week and then increased at weekly intervals to up to four times a day, according to individual lesion tolerance. Sufficient gel should be applied to cover the lesion with a generous coating. The gel should be allowed to dry before covering the lesion with clothing. Occlusive dressings should not be used with Targretin gel. Because unaffected skin may become irritated, avoid applying the gel to normal skin surrounding the lesions. In addition, the gel should not be applied to mucosal surfaces of the body. A response may be seen as soon as four weeks after initiation of therapy, but most patients require longer application. With continued application, further benefit may be obtained. The most common adverse events include rash, pruritis, skin disorder, and pain at the site of application. Targretin gel 1% is supplied in tubes containing 60 g (600 mg active bexarotene).
Targretin gel is the third drug marketed by Ligand Pharmaceuticals for the treatment of cutaneous T-cell lymphoma. Ligand Pharmaceuticals also manufactures Ontak® (denileukin diftitox), an IV treatment indicated for late-stage disease, and Targretin® (bexarotene) capsules, an oral treatment indicated for all stages of disease. Targretin gel is the only topical therapy approved by the FDA for treating patients with cutaneous T-cell lymphoma. For more information, contact Ligand Pharmaceuticals at 800-964-5836 or visit its Web site at http://www.ligand.com/
